Drug Search Results
More Filters [+]

Alprostadil

Alternative Names: alprostadil, prostaglandin e1, prostavasin, pge-1, femlife, liprostin, vitaros, muse, caverject, edex, caverject impulse
Latest Update: 2024-11-06
Latest Update Note: Clinical Trial Update

Product Description

Alprostadil is a medication used in the management and treatment of erectile dysfunction in males and for temporary patency of ductus arteriosus in newborns with congenital heart diseases before surgical intervention. It is in the prostaglandin analog class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK542217/)

Mechanisms of Action: EP1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: Erectile Dysfunction

Known Adverse Events: Pain Unspecified

Company: CSPC
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Alprostadil

Countries in Clinic: China

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Acute Kidney Injury|Optic Neuropathy, Ischemic

Phase 1: Angina Pectoris|Atherosclerosis|Chronic Pain|Ductus Arteriosus, Patent|Heart Failure, Chronic|Microvascular Angina|Myocardial Infarction|Retinal Vein Occlusion|Thrombosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PG-NAION

P2

Active, not recruiting

Optic Neuropathy, Ischemic

2020-05-18

CTR20221833

P2

Recruiting

Acute Kidney Injury

None

CTR20132242

P1

Recruiting

Thrombosis|Microvascular Angina|Atherosclerosis|Angina Pectoris|Ductus Arteriosus, Patent|Chronic Pain|Retinal Vein Occlusion|Heart Failure, Chronic|Myocardial Infarction

None

Recent News Events